Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human ApoA1 Protein, 1mg  

Recombinant human ApoA1 Protein, 1mg

Recombinant Human Apo-A1 Protein (Human Apo-A1, His Tag) Arg 19 - Gln 267 was produced in human 293 cells (HEK293)

Synonym: recombinant, human, protein Apolipoprotein A-I, APOA1

More details

AP1-H5225-1K

Availability: within 7 days

2 100,00 €

Background
ApoA1 is also known as apolipoprotein A-I, ApoA-I , and is the major protein component of high density lipoprotein (HDL) in plasma. It has a specific role in lipid metabolism. Chylomicrons secreted from the intestinal enterocyte also contain ApoA1 but it is quickly transferred to HDL in the bloodstream [1]. The protein promotes cholesterol efflux from tissues to the liver for excretion. It is a cofactor for lecithin cholesterolacyltransferase (LCAT) which is responsible for the formation of most plasma cholesteryl esters. ApoA-I was also isolated as a prostacyclin (PGI2) stabilizing factor, and thus may have an anticlotting effect.[2] Defects in the gene encoding it are associated with HDL deficiencies, including Tangier disease, and with systemic non-neuropathic amyloidosis.[3] In addition, it has been shown that ApoA1 is implicated in the anti-endotoxin function of HDL via interaction with lipopolysaccharide or endotoxin. [4]

Source
Recombinant Human Apo-A1 Protein (Human Apo-A1, His Tag) Arg 19 - Gln 267 (Accession # NP_000030.1) was produced in human 293 cells (HEK293).

Molecular Characterization
rhApoA1, a 250 amino acids protein with polyhistidine tag at C-terminus, and has a calculated MW of 29 kDa. The predicted N-terminus is Asp25. DTT-reduced protein migrates as 26-30 kDa protein.

Endotoxin
Less than 1.0 EU per μg of the rhApoA1 by the LAL method.

Purity
>92% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
Avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C-8°C); After reconstitution under sterile conditions for 1 month (4°C-8°C) or 3 months (-20°C to -70°C).

Bioactivity
n/a

References

(1) Wasan KM , et al. 2008, Nature Reviews Drug Discovery 7 (1): 84–99.
(2) Yui Y, et al. 1988, J. Clin. Invest. 82 (3): 803–7.
(3) Eggerman, T.L. et al., 1991, J. Lipid Res. 32: 821-828.
(4) Voyiaziakis, E. et al., 1998. J. Lipid Res. 39: 313-321.